Next Article in Journal
Cone Dystrophies: An Optical Coherence Tomography Angiography Study
Previous Article in Journal
Contemporary Management of Acute Lower Limb Ischemia: Determinants of Treatment Choice
Previous Article in Special Issue
Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer
Open AccessReview

Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells

Unit of Gynaecological Oncology Research, European Institute of Oncology IRCSS, 20128 Milan, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1502; https://doi.org/10.3390/jcm9051502
Received: 2 April 2020 / Revised: 7 May 2020 / Accepted: 13 May 2020 / Published: 16 May 2020
L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several tumor types where it is causally linked to malignancy and therapy resistance, acting also as a poor prognosis factor. Accordingly, several approaches have been developed to interfere with L1CAM function or to deliver cytotoxic agents to L1CAM-expressing tumors. Metastatic dissemination, tumor relapse and drug resistance can be fueled by a subpopulation of neoplastic cells endowed with peculiar biological properties that include self-renewal, efficient DNA repair, drug efflux machineries, quiescence, and immune evasion. These cells, known as cancer stem cells (CSC) or tumor-initiating cells, represent, therefore, an ideal target for tumor eradication. However, the molecular and functional traits of CSC have been unveiled only to a limited extent. In this context, it appears that L1CAM is expressed in the CSC compartment of certain tumors, where it plays a causal role in stemness itself and/or in biological processes intimately associated with CSC (e.g., epithelial-mesenchymal transition (EMT) and chemoresistance). This review summarizes the role of L1CAM in cancer focusing on its functional contribution to CSC pathophysiology. We also discuss the clinical usefulness of therapeutic strategies aimed at targeting L1CAM in the context of anti-CSC treatments. View Full-Text
Keywords: L1CAM; cancer stem cells; chemoresistance; epithelial-mesenchymal transition; cancer therapy; cell adhesion molecule L1CAM; cancer stem cells; chemoresistance; epithelial-mesenchymal transition; cancer therapy; cell adhesion molecule
Show Figures

Figure 1

MDPI and ACS Style

Giordano, M.; Cavallaro, U. Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells. J. Clin. Med. 2020, 9, 1502.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop